0      0

JL1106EH - JL1106EH: Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status

Full author listing

Reid W. Merryman, MD,1* David Belada, MD, PhD,2 Anna Sureda, MD, PhD,3 Sirpa Leppä, MD, PhD,4 Joost S.P. Vermaat, MD, PhD,5 Harald Holte, MD, PhD,6 Martin Hutchings, MD, PhD,7 Pieternella Lugtenburg, MD, PhD,8 Sven de Vos, MD, PhD,9 Pau Abrisqueta, MD, PhD,10 Marcel Nijland, MD, PhD,11 Jacob Haaber Christensen, MD, PhD,12 Björn E. Wahlin, MD, PhD,13 Kim M. Linton, MBChB, PhD,14 Liwei Wang, PhD,15 Aqeel Abbas, MS,15 Ali Rana, MD, PhD,15 Syed Quadri, PharmD,16 Lorenzo Falchi, MD17

1Dana-Farber Cancer Institute, Boston, MA, USA; 24th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic; 3Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain; 4University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; 5Leiden University Medical Center, Leiden, Netherlands; 6Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, Oslo, Norway; 7Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 8On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands; 9Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA, USA; 10Hospital Universitario Vall d’Hebron, Barcelona, Spain; 11University Medical Center Groningen and University of Groningen, Groningen, Netherlands; 12Odense University Hospital, Odense, Denmark; 13Karolinska Institutet,

Stockholm, Sweden; 14The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, UK; 15Genmab, Princeton, NJ, USA; 16AbbVie, North Chicago, IL, USA; 17Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

*Corresponding author.


You must be logged in and own this session in order to post comments.